Posts for keyword:

Nivolumab

Microbiota and immunotherapy

AACR 2019: Fecal microbiota transplantation for anti-PD-1 therapy refractory melanoma

For patients with metastatic melanoma who fail to durably respond to PD-1 inhibitors, fecal microbiota transplantation (FMT) combined with reintroduction of anti-PD-1 therapy seems promising.

Neoadjuvant nivolumab safe in resectable NSCLC

Neoadjuvant nivolumab was safe, and yielded pathologic responses in patients with resectable lung cancer.

Drew Pardoll on neoadjuvant nivolumab in stage 1-3 NSCLC

The neoadjuvant PD-1 blockade in resectable lung cancer led to major pathological responses in 45 percent of the patients enrolled in a clinical trial.

First-line pembro + chemo improved survival in KEYNOTE-189

KEYNOTE-189 met its dual primary endpoints of overall survival and progression-free survival in newly diagnosed metastatic NSCLC.

Improved PFS with nivo + ipi in patients with advanced NSCLC with high TMB

Patients with newly diagnosed advanced NSCLC with high tumor mutational burden had significantly improved PFS with nivolumab plus ipilimumab.

Checkpoint inhibitors and platinum as first line treatment for NSCLC

Combinations of immune checkpoint inhibitors and chemotherapy show promising results. Results of the the KEYNOE 189 study will be presented at the AACR.

Immune therapy for advanced colorectal cancer (mCRC)

Immune checkpoint inhibitors show promise in the treatment of rare mCRC cases with high microsatellite instability.